News headlines about The Advisory Board (NASDAQ:ABCO) have trended positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. The Advisory Board earned a media sentiment score of 0.26 on Accern’s scale. Accern also assigned headlines about the business services provider an impact score of 46.260869692814 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern’s scoring:
- Inflazome Appoints Renowned Harvard Cardiologist to its Scientific Advisory Board (markets.financialcontent.com)
- Analyzing Everi (EVRI) & The Advisory Board (ABCO) (americanbankingnews.com)
- Checkpoint Systems (CKP) and The Advisory Board (ABCO) Head to Head Comparison (americanbankingnews.com)
- Dr. Brian O’Connor Joins Veritas Pharma Advisory Board (markets.financialcontent.com)
- ThreeD Capital Adds Frank Dumas To Advisory Board (markets.financialcontent.com)
A number of brokerages recently issued reports on ABCO. Wells Fargo & Co cut The Advisory Board from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $57.00 to $54.00 in a research note on Monday, October 2nd. Cantor Fitzgerald restated a “hold” rating on shares of The Advisory Board in a research note on Friday, November 17th. Finally, Robert W. Baird restated a “hold” rating and issued a $54.00 price objective on shares of The Advisory Board in a research note on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $51.95.
The Advisory Board (NASDAQ ABCO) opened at $53.83 on Friday. The Advisory Board has a twelve month low of $30.40 and a twelve month high of $59.50. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $2,190.00, a PE ratio of 30.94, a PEG ratio of 2.40 and a beta of 1.34.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://transcriptdaily.com/2018/01/05/positive-press-coverage-somewhat-unlikely-to-affect-the-advisory-board-abco-share-price.html.
The Advisory Board Company Profile
The Advisory Board Company is a provider of software and solutions to the healthcare and higher education industries. The Company offers subscription-based membership programs, software and data-enabled services. All of its programs are rooted in best practices and extends across four areas, including Best practices research, Technology, Data-enabled services and Consulting services.
Receive News & Ratings for The Advisory Board Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Advisory Board and related companies with MarketBeat.com's FREE daily email newsletter.